Anti-CLL1 CAR T cell therapy(Soochow University)

N/A

Report date: 2022/08/30 20:00:42

Base Information

Drug NameAnti-CLL1 CAR T cell therapy(Soochow University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionC-Type lectin domain family 12 member A modulators

TargetsC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesThe First Affiliated Hospital Of Soochow University

China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Soochow University

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A